Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

eMI Aesthetics vs June Health

eMI Aesthetics
Graded #104

Higher grade

vs+7.299999999999997
June Health
Graded #261

Lower grade

The verdict

eMI Aesthetics takes it — 70.3/100 to 63/100.

eMI Aesthetics grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMI Aesthetics is a US direct-to-consumer telehealth brand offering doctor-guided GLP-1 weight loss programs to eligible patients in all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueeMI Aesthetics +12
73
61
Dose & formulationeMI Aesthetics +9
84
75
Clinical oversighteMI Aesthetics +11
70
59
Labs & monitoringEven
51
51
FulfillmenteMI Aesthetics +3
77
74
Contract termsEven
55
55
eMI Aesthetics · left barJune Health · right bar

The numbers

MetriceMI AestheticsJune Health
WeighScore70.3/10063/100
GradeCC
Scorecard rank#104#261
Semaglutide$179/mo (all doses, compounded)$179/mo (starting dose, compounded)
TirzepatideNot disclosed$179/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
eMI Aesthetics

Graded #104 · C

Strengths

  • Available to eligible patients in all 50 states
  • Offers both semaglutide and tirzepatide, plus an oral semaglutide option
  • Intake and provider visits run through OpenLoop Health, an established telehealth network

Where it loses points

  • Full per-drug pricing is not shown before intake; only an 'as low as 179/month' starting rate is published
  • No fill pharmacy or named medical director is publicly listed
  • Support appears limited to email, with no phone number or hours published
June Health

Graded #261 · C

Strengths

  • Offers both injectable and oral compounded semaglutide and tirzepatide
  • Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
  • Full per-dose price list published on-site with no signup required to view it
  • Provider consult ('licensed clinician evaluation') is bundled into the displayed price
  • Free discreet shipping advertised with 2-3 day delivery

Where it loses points

  • No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
  • No LegitScript seal or other pharmacy-verification badge found anywhere on the site
  • Legal entity, prescribing medical group, and compounding pharmacy partner are not named
  • Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
  • Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard